LAPATAX: A randomized phase II trial of FEC-docetaxel combined with lapatinib and/or trastuzumab as neoadjuvant therapy of HER2-positive breast cancer—EORTC 10054 trial.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. TPS116-TPS116 ◽  
Author(s):  
D. A. Cameron ◽  
S. Marreaud ◽  
K. Zaman ◽  
A. Bodmer ◽  
J. Pierga ◽  
...  
2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 576-576 ◽  
Author(s):  
A. De Censi ◽  
M. Puntoni ◽  
G. Pruneri ◽  
A. Guerrieri-Gonzaga ◽  
M. Cazzaniga ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document